Prizloncabtagene Autoleucel
Phase 2Cell therapy
Johnson & JohnsonPrizloncabtagene Autoleucel is one of 49 biologic programs targeting Lymphoma, Non-Hodgkin. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Cabenuva
GSKPreclinical
Prizloncabtagene Autoleucel
Johnson & JohnsonPhase 2
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma4 trials
Safety and Efficacy1 trial
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Completed·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1·NCT04317885·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prizloncabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company